• Explore /
  • Poster
  • / Naxitamab and granulocyte macrophage colony stimulating factor (GM-CSF) in combination with irinotecan and temozolomide in patients with high-risk neuroblastoma with primary refractory disease or in first relapse: An international, single-arm, multicenter phase 2 trial.

Naxitamab and granulocyte macrophage colony stimulating factor (GM-CSF) in combination with irinotecan and temozolomide in patients with high-risk neuroblastoma with primary refractory disease or in first relapse: An international, single-arm, multicenter phase 2 trial.

Abstract Poster

Authors

null

Godfrey Chi-Fung Chan

Hong Kong Children's Hospital, The University of Hong Kong, Hong Kong, Hong Kong

Godfrey Chi-Fung Chan , Charlotte Hindsberger , Anni Morsing , Steen Lisby

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Pediatric Oncology

Track

Pediatric Oncology

Sub Track

Pediatric Solid Tumors

Clinical Trial Registration Number

NCT04560166

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS10061)

DOI

10.1200/JCO.2022.40.16_suppl.TPS10061

Abstract #

TPS10061

Poster Bd #

273b

Abstract Disclosures

Similar Posters

First Author: Shakeel Modak

First Author: Jaume Mora

First Author: Steven G. DuBois

First Author: Lucas Moreno